Related references
Note: Only part of the references are listed.Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma:: results of a randomised phase III trial (OSHO# 19)
M Herold et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2006)
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
W Hiddemann et al.
BLOOD (2005)
New treatment options have changed the survival of patients with follicular lymphoma
RI Fisher et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Second primary malignancies after treatment for malignant lymphoma
A Okines et al.
BRITISH JOURNAL OF CANCER (2005)
Improved survival of follicular lymphoma patients in the United States
WT Swenson et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha
P McLaughlin et al.
BLOOD (2005)
Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab
JM Bennett et al.
BLOOD (2005)
Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma
MJ Rummel et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma - A randomized phase II trial of the minnie pearl cancer research network
JD Hainsworth et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma
R Marcus et al.
BLOOD (2005)
Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-Cell lymphoma, progressive after rituximab
SJ Horning et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Bendamustine plus mitoxantrone -: A new effective treatment for advanced chronic lymphocytic leukaemia:: Results of a phase I/II study
H Köppler et al.
LEUKEMIA & LYMPHOMA (2004)
Follicular lymphoma international prognostic index
P Solal-Céligny et al.
BLOOD (2004)
Fludarabine and bendamustine in refractory and relapsed indolent lymphoma -: a multicenter phase I/II trial of the East German society of Hematology and Oncology (OSHO)
M Koenigsmann et al.
LEUKEMIA & LYMPHOMA (2004)
Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly X 4 schedule
M Ghielmini et al.
BLOOD (2004)
Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients
JO Armitage et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas
K Bremer
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2002)
Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma
SM Ansell et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma
TE Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Bendamustine in the treatment of non-hodgkin's lymphoma: Results and future perspectives
MJ Rummel et al.
SEMINARS IN ONCOLOGY (2002)
Successful autologous peripheral blood stem cell transplantation in transformed follicular lymphoma previously treated with radioimmunotherapy (iodine I-131 tositumomab)
J Cooney et al.
BONE MARROW TRANSPLANTATION (2002)
Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas
A Heider et al.
ANTI-CANCER DRUGS (2001)
Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia
R Kath et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2001)
Share Paper
